PDL BioPharma, Inc. Share buybacks
- Total buybacks · last 12 months (USD): Value (m); Formula and calculation Trailing-year cash paid for share repurchases. Period ending 2020-08-31..
- Buyback yield · 12 months: Value (m); Formula and calculation Cash paid for share repurchases / current market cap. Period ending 2020-08-31..
Share buybacks
Overview →Financial period ending 2020-08-31; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Total buybacks · last 12 months (USD) | (m) | Trailing-year cash paid for share repurchases. Period ending 2020-08-31. |
| Buyback yield · 12 months | (m) | Cash paid for share repurchases / current market cap. Period ending 2020-08-31. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Buybacks · 12 months | (m) | Payments for Repurchase of Common Stock |
| Market cap | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Total buybacks | Market cap (USD) | Buyback yield |
|---|---|---|---|
| 2020-08-31 | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) |
| 2019-12-31 | $86.90M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) |
| 2018-12-31 | $49.11M | (m) | (m) |
| 2018-09-30 | (m) | (m) | (m) |
| 2018-06-30 | (m) | (m) | (m) |
| 2018-03-31 | (m) | (m) | (m) |
| 2017-12-31 | $30.00M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) |
| 2016-12-31 | $0.00 | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) |
| 2015-12-31 | $0.00 | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.